Abemaciclib for NF1 tumors using pills and body scans
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NF1, confirmed by having at least two NF1 signs (like café-au-lait spots, freckles in skin folds, neurofibromas, optic pathway glioma, or other specific findings) or a proven NF1 genetic change.
- You have at least one “measurable” atypical neurofibroma that is about 3 cm or larger in one direction, and it can be measured using an MRI scan.
- You are at least 12 years old (and able to swallow whole tablets; for some younger patients a biopsy may be needed if it can be done safely).
- Your heart, blood counts, liver, and kidney tests are within study limits, and you can meet the trial’s timing rules after prior treatments.
- You have not had abemaciclib (or another CDK4/6 inhibitor) before, and you’re able to follow study safety rules (including avoiding grapefruit).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.